Israeli biotechnology company Kadimastem has been granted a United States patent for its technology used in stem cell treatment for multiple sclerosis (MS) and other neurodegenerative diseases.
This technology provides an innovative method of producing supporting cells in the central nervous system from stem cells, including myelin-producing cells.
The technology was created by Professor Michel Revel, the company’s Chief Scientist, at the Weizmann Institute, and Yeda Research and Development Company own the patent. According to an agreement between Kadimastem and Yeda, the company has been granted an exclusive license for use and it joins additional patents that have also been granted by Israel and Europe.
Kadimastem is developing innovative treatments for a number of neurodegenerative diseases by transplanting cells and tissues differentiated from human stem cells.
Yossi Ben-Yossef, Kadimastem's CEO, said: “With the company's preparations for the first clinical trial of its unique product, the reinforcement of the company's IP is particularly important. The United States is a target market for the company's products for several reasons, including regulatory (the company will conduct the trial according to the outline coordinated with the FDA), strategic collaborations, potential investors and market size. The patent granted in the United States is a substantial asset in each of these aspects.”
Professor Michel Revel added: “The granting of the patent is an international recognition of the uniqueness of the technology at the basis of the cell based treatment for ALS, which Kadimastem develops toward the upcoming clinical trial. The patent also has applications in additional nervous system diseases, and it reinforces the company’s position in the field.”
Source: MS-UK (23/03/17)